- Page 1 and 2: Model Organisms in Drug Discovery M
- Page 3 and 4: Copyright u 2003 John Wiley & Sons
- Page 5 and 6: Contents List of contributors .....
- Page 7: CONTENTS ix 7 Genetics and Genomics
- Page 11 and 12: LIST OF CONTRIBUTORS xiii Stefan Sc
- Page 13 and 14: 1 Introduction to Model Systems in
- Page 15 and 16: Organism INTEGRATING MODEL ORGANISM
- Page 17 and 18: INTEGRATING MODEL ORGANISM RESEARCH
- Page 19 and 20: INTEGRATING MODEL ORGANISM RESEARCH
- Page 21 and 22: 10 GROWING YEAST FOR FUN AND PROFIT
- Page 23 and 24: 12 GROWING YEAST FOR FUN AND PROFIT
- Page 25 and 26: 14 GROWING YEAST FOR FUN AND PROFIT
- Page 27 and 28: 16 GROWING YEAST FOR FUN AND PROFIT
- Page 29 and 30: 18 GROWING YEAST FOR FUN AND PROFIT
- Page 31 and 32: 20 GROWING YEAST FOR FUN AND PROFIT
- Page 33 and 34: 22 GROWING YEAST FOR FUN AND PROFIT
- Page 35 and 36: 24 GROWING YEAST FOR FUN AND PROFIT
- Page 37 and 38: 26 GROWING YEAST FOR FUN AND PROFIT
- Page 39 and 40: 28 GROWING YEAST FOR FUN AND PROFIT
- Page 41 and 42: 30 GROWING YEAST FOR FUN AND PROFIT
- Page 43 and 44: 32 GROWING YEAST FOR FUN AND PROFIT
- Page 45 and 46: 34 GROWING YEAST FOR FUN AND PROFIT
- Page 47 and 48: 36 GROWING YEAST FOR FUN AND PROFIT
- Page 49 and 50: 38 GROWING YEAST FOR FUN AND PROFIT
- Page 51 and 52: 3 Caenorhabditis elegans Functional
- Page 53 and 54: THE DRUG DISCOVERY PROCESS 43 thoug
- Page 55 and 56: multivulva phenotype of Ras gain-of
- Page 57 and 58: disease. These molecular targets ar
- Page 59 and 60:
FROM DISEASE TO TARGET 49 Figure 3.
- Page 61 and 62:
FROM DISEASE TO TARGET 51 Figure 3.
- Page 63 and 64:
signaling pathway. The third catego
- Page 65 and 66:
FROM DISEASE TO TARGET 55 resistant
- Page 67 and 68:
phenomenon was first observed in C.
- Page 69 and 70:
profiles. The C. elegans gene expre
- Page 71 and 72:
emerging technologies. Forward gene
- Page 73 and 74:
The compound library LEAD DISCOVERY
- Page 75 and 76:
LEAD DISCOVERY 65 previous section,
- Page 77 and 78:
LEAD DISCOVERY 67 Figure 3.5 Distri
- Page 79 and 80:
Compound learning set for assay val
- Page 81 and 82:
10 000-15 000 human drug targets ar
- Page 83 and 84:
transporter itself. The SSRIs that
- Page 85 and 86:
REFERENCES 75 de Montigny, C., Blie
- Page 87 and 88:
REFERENCES 77 Lewis, J. A., Wu, C.
- Page 89 and 90:
REFERENCES 79 Tissenbaum, H. A. and
- Page 91 and 92:
82 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 93 and 94:
84 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 95 and 96:
86 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 97 and 98:
88 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 99 and 100:
90 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 101 and 102:
92 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 103 and 104:
94 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 105 and 106:
96 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 107 and 108:
98 DROSOPHILA AS A TOOL FOR DRUG DI
- Page 109 and 110:
100 DROSOPHILA AS A TOOL FOR DRUG D
- Page 111 and 112:
102 DROSOPHILA AS A TOOL FOR DRUG D
- Page 113 and 114:
104 DROSOPHILA AS A TOOL FOR DRUG D
- Page 115 and 116:
106 DROSOPHILA AS A TOOL FOR DRUG D
- Page 117 and 118:
108 DROSOPHILA AS A TOOL FOR DRUG D
- Page 119 and 120:
110 DROSOPHILA AS A TOOL FOR DRUG D
- Page 121 and 122:
112 DROSOPHILA AS A TOOL FOR DRUG D
- Page 123 and 124:
114 DROSOPHILA AS A TOOL FOR DRUG D
- Page 125 and 126:
116 DROSOPHILA AS A TOOL FOR DRUG D
- Page 127 and 128:
5 Drosophila - a Model System for T
- Page 129 and 130:
EVOLUTIONARY CONSERVATION OF DISEAS
- Page 131 and 132:
EVOLUTIONARY CONSERVATION OF DISEAS
- Page 133 and 134:
EVOLUTIONARY CONSERVATION OF DISEAS
- Page 135 and 136:
EVOLUTIONARY CONSERVATION OF DISEAS
- Page 137 and 138:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 139 and 140:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 141 and 142:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 143 and 144:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 145 and 146:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 147 and 148:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 149 and 150:
TARGET IDENTIFICATION/TARGET VALIDA
- Page 151 and 152:
CHEMICAL GENETICS 143 acid identity
- Page 153 and 154:
3. A hit identifies a biologically
- Page 155 and 156:
about their function in a multicell
- Page 157 and 158:
REFERENCES 149 Han, Z. S., Enslen,
- Page 159 and 160:
REFERENCES 151 Rintelen, F., Stocke
- Page 161 and 162:
6 Mechanism of Action in Model Orga
- Page 163 and 164:
INTRODUCTION TO COMPOUND DEVELOPMEN
- Page 165 and 166:
MODEL ORGANISMS ARRIVE ON THE SCENE
- Page 167 and 168:
ELUCIDATING THE MECHANISM OF COMPOU
- Page 169 and 170:
ELUCIDATING THE MECHANISM OF COMPOU
- Page 171 and 172:
A CASE STUDY FOR ALZHEIMER’S DISE
- Page 173 and 174:
A CASE STUDY FOR ALZHEIMER’S DISE
- Page 175 and 176:
A CASE STUDY FOR ALZHEIMER’S DISE
- Page 177 and 178:
A CASE STUDY FOR ALZHEIMER’S DISE
- Page 179 and 180:
NEW CHEMICAL GENETIC STRATEGIES 171
- Page 181 and 182:
A CASE STUDY FOR INNATE IMMUNITY 17
- Page 183 and 184:
GLOBAL GENE EXPRESSION STUDIES IN M
- Page 185 and 186:
As described above, the extensive i
- Page 187 and 188:
REFERENCES 179 Austin, J. and Kimbl
- Page 189 and 190:
REFERENCES 181 Hughes, T. R., Marto
- Page 191 and 192:
REFERENCES 183 Sin, N., Meng, L., W
- Page 193 and 194:
186 GENETICS AND GENOMICS IN THE ZE
- Page 195 and 196:
188 GENETICS AND GENOMICS IN THE ZE
- Page 197 and 198:
190 GENETICS AND GENOMICS IN THE ZE
- Page 199 and 200:
192 GENETICS AND GENOMICS IN THE ZE
- Page 201 and 202:
194 GENETICS AND GENOMICS IN THE ZE
- Page 203 and 204:
196 GENETICS AND GENOMICS IN THE ZE
- Page 205 and 206:
198 GENETICS AND GENOMICS IN THE ZE
- Page 207 and 208:
200 GENETICS AND GENOMICS IN THE ZE
- Page 209 and 210:
8 Lipid Metabolism and Signaling in
- Page 211 and 212:
FISH AS A MODEL ORGANISM 205 genes
- Page 213 and 214:
LIPID METABOLISM SCREEN 207 transpo
- Page 215 and 216:
LIPID METABOLISM SCREEN 209 Figure
- Page 217 and 218:
the embryo media containing radioac
- Page 219 and 220:
ZEBRAFISH AS A MODEL SYSTEM 213 Fig
- Page 221 and 222:
ZEBRAFISH AS A MODEL SYSTEM 215 Reg
- Page 223 and 224:
aspirin, which has potent inhibitor
- Page 225 and 226:
REFERENCES 219 Chau, I. and Cunning
- Page 227 and 228:
REFERENCES 221 Patrono, C., Patrign
- Page 229 and 230:
224 CHEMICAL MUTAGENESIS IN THE MOU
- Page 231 and 232:
226 CHEMICAL MUTAGENESIS IN THE MOU
- Page 233 and 234:
228 CHEMICAL MUTAGENESIS IN THE MOU
- Page 235 and 236:
230 CHEMICAL MUTAGENESIS IN THE MOU
- Page 237 and 238:
232 CHEMICAL MUTAGENESIS IN THE MOU
- Page 239 and 240:
234 CHEMICAL MUTAGENESIS IN THE MOU
- Page 241 and 242:
236 CHEMICAL MUTAGENESIS IN THE MOU
- Page 243 and 244:
238 CHEMICAL MUTAGENESIS IN THE MOU
- Page 245 and 246:
240 CHEMICAL MUTAGENESIS IN THE MOU
- Page 247 and 248:
242 CHEMICAL MUTAGENESIS IN THE MOU
- Page 249 and 250:
244 CHEMICAL MUTAGENESIS IN THE MOU
- Page 251 and 252:
246 CHEMICAL MUTAGENESIS IN THE MOU
- Page 253 and 254:
248 CHEMICAL MUTAGENESIS IN THE MOU
- Page 255 and 256:
250 CHEMICAL MUTAGENESIS IN THE MOU
- Page 257 and 258:
252 SATURATION SCREENING OF DRUGGAB
- Page 259 and 260:
254 SATURATION SCREENING OF DRUGGAB
- Page 261 and 262:
256 SATURATION SCREENING OF DRUGGAB
- Page 263 and 264:
258 SATURATION SCREENING OF DRUGGAB
- Page 265 and 266:
260 SATURATION SCREENING OF DRUGGAB
- Page 267 and 268:
262 SATURATION SCREENING OF DRUGGAB
- Page 269 and 270:
264 SATURATION SCREENING OF DRUGGAB
- Page 271 and 272:
266 SATURATION SCREENING OF DRUGGAB
- Page 273 and 274:
268 SATURATION SCREENING OF DRUGGAB
- Page 275 and 276:
270 SATURATION SCREENING OF DRUGGAB
- Page 277 and 278:
272 SATURATION SCREENING OF DRUGGAB
- Page 279 and 280:
274 SATURATION SCREENING OF DRUGGAB
- Page 281 and 282:
276 SATURATION SCREENING OF DRUGGAB
- Page 283 and 284:
278 SATURATION SCREENING OF DRUGGAB
- Page 285 and 286:
280 INDEX bupropion 92 busulfan 143
- Page 287 and 288:
282 INDEX Dscam 171 dual-energy X-r
- Page 289 and 290:
284 INDEX L-685,818 16 lead discove
- Page 291 and 292:
286 INDEX protein function 19-22 pr
- Page 293:
288 INDEX yeast (continued) functio